CHRONIC WOUND CARE FROM THE INSIDE OUT

Linda Martien, CPC, CPC-H, CPMA, CEDC

WELCOME TO WOUND CARE 201

Index
- Terminology
- Anatomy
- Surgical Treatment
- Medical Treatment
- Hyperbaric Oxygen Therapy
- Skin Substitutes
### WOUND CARE TERMINOLOGY

#### Acute vs. Chronic
- Acute
- Chronic

#### Levels of skin and underlying tissues
- Partial thickness
- Full thickness
- Subcutaneous
- Muscle
- Bone

#### Gunk
- Fibrin, slough, eschar

#### Types of ulcers
- Pressure
- Diabetic
- Other

#### Grafts
- Autograft
- Homograft
- Allograft
- Xenograft
- Bone

#### Big gunk
- Infection, abscess, gangrene

### ACRONYMS 101

- RS – Reimbursement Specialist
- RCM – Revenue Cycle Management
- FI – Fiscal Intermediary
- MAC – Medicare Administrative Contractor
- LCD – Local Coverage Determination
- NCD – National Coverage Determination
- EOB – Explanation of Benefits
- R/A – Remittance Advice
- ADR – Advance Documentation Request
WAIT – THERE’S MORE!

RAC – Recovery Audit Contractor
ABN – Advance Beneficiary Notice
CMS – Centers for Medicare & Medicaid Services
APC – Ambulatory Payment Classification
E/M – Evaluation & Management
UB04 – Uniform Billing Form for hospitals
1500 – Universal Billing Form for physicians
CDM – Charge Description Master

ANATOMY OF THE SKIN

[Diagram of skin cross-section with labeled components]

©TheBootsLearning.com
PHYSIOLOGY OF HEALING

1. Hemostasis
   - Vasoconstriction, platelet release, clot formation

2. Inflammation
   - Vasodilation
   - Neutrophils appear to destroy dying cells
   - Macrophages clean the ulcer and produce growth factors

3. Proliferation
   - Angiogenesis
   - Fibroblasts synthesize collagen fibers
   - Collagen fibers produce keratinocyte

4. Maturation
   - Shrinking and strengthening of the scar

CHRONIC VS. ACUTE WOUNDS

A. Acute Wound
B. Chronic (non-healing) Wound
BUT IS IT REALLY A WOUND?

Wound – arises from trauma
Ulcer – has an underlying etiology
Burn – is a burn, is a burn, is a burn

These are each coded differently and some require additional codes, such as E codes (External Causes)

WOUND = REMOVAL/LOSS OF TISSUE

Coded to the:

- Status of wound, superficial or open
  - Superficial
    - Abrasion
    - Blisters
    - Bites
    - Scratch
  - Open
    - Lacerations
    - Punctures
    - Dehiscence
    - Incisions

- Complexity of the wound
  - Simple
  - Intermediate
  - Complex
WOUND CODING

Superficial
- Simple
- Intermediate
- Complex

Open
- Simple
- Intermediate
- Complex

WOUND VS. ULCER

Wound – Open wound of the foot
- Wound
- Open
  - Foot (any part except toe[s]) alone – 892.0
  - With tendon involvement – 892.2
    - Complicated 892.1
- How and where?
- External Cause
  - E920.8 – Other specified cutting or piercing instruments (glass)
- Place of Occurrence
  - E849.3 – yard

Ulcer – Diabetic ulcer of the plantar midfoot, neuropathic complication, type II, controlled
- 250.60
- 707.14

Ulcer – Pressure ulcer of the right lateral ankle (lateral malleolus)
- 707.05
- 707.20
PRESSURE ULCERS

Pressure (Decubitus) 707.00 – 707.09 and 707.20 – 707.25

- Specific to site
- Must be staged
  - 1 – persistent focal erythema
  - 2 – partial thickness skin loss involving epidermis, dermis, or both
  - 3 – full thickness skin loss extending through subcutaneous tissue
  - 4 – necrosis of the soft tissue extending to muscle and bone

PRESSURE ULCER STAGE - I

Stage 1: Nonblanchable erythema (redness that doesn't quickly fade) of intact (unbroken) skin; could also include warmth, swelling. Dark skin might appear discolored instead of red.
PRESSURE ULCER STAGE - II

Stage 2: Superficial (not very deep) ulcers with loss of epidermis (outer layers of skin), dermis (underlying, still developing skin tissue) or both. Might look like a scrape, blister, "zit" or crater.

PRESSURE ULCER STAGE - III

Stage 3: Skin loss to both outer and underlying layers of skin tissue, with damage all the way down to fascia (connective tissue of body).
PRESSURE ULCER STAGE - IV

Stage 4: Skin loss to both outer and underlying layers of skin tissue, with a great deal of damage and dead tissue in the fascia, muscle, bone, tendon or joint capsule.

DIABETIC AND VENOUS ULCERS

Non-pressure (DFU and VLU) 707.10 – 707.19
Specific to site
707.10 – lower limb, unspecified
707.11 – ulcer of thigh
707.12 – ulcer of calf
707.13 – ulcer of ankle
707.14 – ulcer of heel and midfoot
707.15 – ulcer of other part of foot
707.19 – ulcer of other part of lower limb
DIABETIC AND VENOUS ULCERS

- Must code underlying etiology
  - Atherosclerosis of extremities with ulceration (440.23)
  - Chronic venous hypertension with ulceration (459.31)
  - Chronic venous hypertension with ulceration and inflammation (459.33)
  - Diabetes mellitus (249.80 – 249.81, 250.80 – 250.83)
  - Postphlebitic syndrome with ulcer (459.11)
  - Postphlebitic syndrome with ulcer and inflammation (459.13)

DIABETIC ULCER WAGNER GRADES

0  No open lesions: may have deformity or cellulitis
1  Superficial ulcer
2  Deep ulcer to tendon or joint capsule
3  Deep ulcer with abscess, osteomyelitis, or joint sepsis
4  Local gangrene – forefoot or heel
5  Gangrene of entire foot

Grade 1 ulcers are superficial ulcers that may span the full thickness of the skin or only partial thickness.
DOCUMENTATION

• The medical record is the main document validating care and treatment provided.
• Documentation provides the opportunity to state the decision making process and the results of treatment.
• The medical record documentation will be the primary document used to defend a lawsuit.
• It is used to determine reimbursement
• Provides information for quality assurance/peer review.
• Demonstrates compliance with applicable regulatory and accrediting agency requirements. (The Joint Commission, CMS, State Law – Title 22)

DOCUMENTATION REQUIREMENTS

Documentation should be legible, maintained in the patient’s medical record and available to Medicare on request and must confirm all requirements in the “Indications and Limitations of Coverage and/or Medical Necessity” section are satisfied re: the clinical characteristics of the ulcer, the presence of qualifying or disqualifying conditions, and nature of and duration of pretreatment conservative management.

• Exact location of each ulcer treated must be included.
DOCUMENTING THE H&P OR PROGRESS NOTE

The H&P
- Chief Complaint (CC)
- History of Present Illness (HPI)
- Review of Systems (ROS)
- Family Social Past History (FSPH)
- Exam
- Medical Decision Making (MDM)

Progress Note
- Chief Complaint (CC)
- Interim History & Physical (H&P)
- Relevant Review of Systems (ROS)
- Exam
- Medical Decision Making (MDM)

EVALUATION & MANAGEMENT

- **New vs. Established Patient – how do you know?**
  - Initial visit or not seen for more than three years by the provider or same specialty provider of the group
- **New**
  - Requires all three key elements
    - History
    - Exam
    - Medical Decision Making
- **Established**
  - Requires two of the three key elements
    - One of which should be Medical Decision Making
NEW VS. ESTABLISHED FURTHER DEFINED

• Newly Revised Definition
  An established patient is one who has received professional services from the physician or another physician of the exact same specialty and subspecialty who belong to the same group practice, within the past three years.

EXAMPLE

• Drs. Green and Blue are in the same cardiology practice. Dr. Green is a general cardiologist. Dr. Blue does electrophysiology exclusively. Dr. Blue has separate boards in EP and the payer has him classified in that specialty. Dr. Green refers a patient to Dr. Blue for consideration of an ICD. Is this a new patient for Dr. Blue?
ANSWER

The patient is “new” to Dr. Blue
- Specialty is not the exact same
- Payer recognizes specialty and physician designation
- There are distinctly subspecialty boards

E/M AUDIT TOOL – HPI AND ROS

HISTORY OF PRESENT ILLNESS (HPI)
- Location
- Quality
- Severity
- Duration
- Timing
- Context
- Modifying Factors
- Associated signs and symptoms

REVIEW OF SYSTEMS (ROS)
- Constitutional
- Eyes
- Ears, nose, mouth, throat
- Card/Vasc
- Resp
- GI
- GU
- Musculo
- Integumentary
- Neuro
- Psych
- Endo
- Hem/lymph
- All / imm
- All Others Neg
E/M AUDIT TOOL – EXAM AND MDM

BODY AREAS
- Head, including face
- Neck
- Chest, including breasts and axillae
- Abdomen

ORGAN SYSTEMS
- Constitutional
- Resp
- Skin
- Back, including spine
- Eyes
- GI
- Neuro
- Each extremity
- Ears, nose, mouth, throat
- GU
- Psych
- Cardiovascular
- Musculo
- Hem / lymph / imm

LOW
- 2 or more self-limited or minor problems.
- 1 stable chronic illness.
- Acute uncomplicated illness or injury

- Physiologic tests not under stress.
- Non-cardiovascular imaging studies with contrast.
- Superficial needle biopsies
- Clinical lab tests requiring arterial puncture
- Skin biopsies

- Over the counter drugs
- Minor surgery with no identified risk factors
- Physical Therapy
- Occupational therapy
- IV fluids without additives

CONSULTS

- Medicare deleted consult codes in 2010
- Commercial payers may still recognize
- Remember the 3 “R’s”
  - Request
  - Response
  - Report
DEBRIDEMENT GOALS

• Wound Cleansing – Remove necrotic tissue
• Reduce bacterial burden – avoid infection
• Provide optimal environment for wound healing
• Removal of MMPs
• Reintroduction of inflammatory phase
• Remove of senescent cells
• To assess extent of wound and determine degree of penetration
• Serial wound bed preparation.

DOCUMENTATION FOR EACH VISIT

Physician Order – Required for all services
• Diagnosis, signature, time and date

Evaluation – Initial
• Initial History and Physical/Interim H&P

Re-evaluation – minimum, every 30 days

Daily Treatment Notes (time with patient)
• Progress Note (Physician Documentation)
• Physician Orders (Physician Documentation)
• Include indications and impression
• Changes in condition, improvements, etc.
• Wound size and details, (photo at least once per month preferred)
• Procedure details
• Signed, dated and timed
DEBRIDEMENT DOCUMENTATION EXAMPLE:

Location
- Anatomic location

Appearance
- Surface dimension and depth
- Presence/absence/extent of granulation tissue, eschar, slough, fibrin
- Presence/absence/extent of obvious signs of infection
- Presence/absence/extent of necrotic, devitalized or non-viable tissue
- Stage or grade where indicated

Anesthesia
- If not used, document why (neuropathy, paraplegia)

Instrument
- Scalpel, scissors, curette, rongeur

Type of tissue removed
- Partial thickness
- Full thickness
- Subcutaneous
- Muscle (includes tendon, ligament)
- Bone

Bleeding and its control

Dressing

Patient tolerance to the procedure

SUBCUTANEOUS

Skin Full Thickness, and Subcutaneous Tissue - 11042, first 20 sq cm
11045; ea add 20 sq cm

Punch Biopsy
Penetrating Wound
Stage III or Grade III
PERI-ULCER HYPERKERATOSIS (CALLUS) WITH ULCER

MUSCLE

Skin, Subcutaneous and Muscle – 11043,
- First 20 sq cm.
- 11046; ea add 20 sq cm
Includes fascia, tendon, joint capsule
Stage IV
BONE

Skin - Subcutaneous Tissue, Muscle and Bone - 11044, first 20 sq cm 11047; ea add 20 sq cm
Not common in clinic setting
Stage IV pressure ulcer
Dehisced surgical wound

OPEN ULCER TO BONE
E/M AND PROCEDURES

• Modifier -25:
  • Appended to the E/M code to indicate a “Significant, separately identifiable service by the same physician on the same day of the procedure or other service”

• What does this mean?
  • “Significant, separately identifiable E/M service above and beyond the other service provided or beyond the usual preoperative and postoperative care associated with the procedure performed…”
  • In other words: Unrelated to the condition or procedure performed”


EXAMPLES:

1. The established patient presents for wound care to include the usual encounter and a subcutaneous debridement. The patient had no complaints and the ulcer is healing satisfactorily. However, upon evaluation, the patient’s blood sugar (by finger stick) was found to be 370. The physician instructs the patient to see his PCP as soon as possible for his diabetes management.

2. The established patient presents for wound care to include the application of Dermagraft®. She has no related complaints and is otherwise doing well. However, on her way into the center she slipped and fell and is now complaining of wrist pain. The doctor examines her and sends her to radiology for an x-ray. The x-ray reveals a non-displaced fracture of the radius. She is sent to an orthopedist for casting and follow up.
SO WHEN CAN YOU BILL FOR AN E/M WITH A PROCEDURE?

1. New patient
2. New problem
3. E/M unrelated to the procedure provided

SELECTIVE DEBRIDEMENT

Active Wound Care Management

- **97597**  Debridement (eg, high pressure water jet, with/without suction, sharp selective debridement with scissors, scalpel and forceps), open wound, (e.g., fibrin, devitalized epidermis and/or dermis, exudate, debris, biofilm), including topical application, wound assessment, use of whirlpool, when performed and instructions for ongoing care, per session, total wound surface first 20 sq cm
- **97598**  ; ea additional 20 sq cm
- **97602**  Removal of devitalized tissue from wounds, non selective debridement, without anesthesia (wet to moist dressings, enzymatic, abrasion), per session
SELECTIVE DEBRIDEMENT/ACTIVE WOUND CARE MANAGEMENT

Skin Partial Thickness – 97597/97598
Epidermis Only
Superficial wound
Stage I pressure ulcer or first degree Burn

SELECTIVE DEBRIDEMENT/ACTIVE WOUND CARE MANAGEMENT

Skin Full Thickness – 97597/97598
Epidermis and Dermis
Example includes healing wounds, a wound which does not penetrate through the subcutaneous layer or blister.
Occasional debridement
UNNA BOOT, COMPRESSION WRAPS & TOTAL CONTACT CASTING

Medicare considers these to be a component of the procedure, regardless if debridement, I & D, application of skin substitutes, etc.

However, there are times when the separate charge is appropriate and should be coded and billed

Commercial payers may consider separate payment

Remember modifier – 51

<table>
<thead>
<tr>
<th>Service Description</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unna Boot</td>
<td>29580</td>
</tr>
<tr>
<td>Compression</td>
<td>29581</td>
</tr>
<tr>
<td>Total Contact Casting</td>
<td>29445</td>
</tr>
</tbody>
</table>

WHEN IT’S APPROPRIATE...

- Debridement of ulcers on the right and left heel with Dermagraft placed on the right heel only. A pressure ulcer of the sacrum was also debrided and a wound vac placed. Bill for the Dermagraft application to the right heel and the debridement of the left heel, and the sacral debridement.

  - 11043 - muscle debridement of the sacrum, first 20 sq cm
  - 11046 - muscle debridement of the sacrum, ea add 20 sq cm x 2
  - 15275-59 Application of Dermagraft, first 20 sq cm
  - 11042-59 subcutaneous debridement left heel, first 20 sq cm

- Debridement of left calf and compression placed bilaterally. Bill for the debridement of the left calf and application of the compression wrap on the right leg:

  - 11042 – subcutaneous debridement, first 20 sq cm
  - 29581-59-RT – application of multi layer compression system
NEGATIVE PRESSURE WOUND THERAPY

Wound vac

- 97605  Negative pressure wound therapy (eg. vacuum assisted drainage collection), including topical applications, wound assessment,... total wound surface area less than or greater to 50 sq cm

- 97606  ; greater than 50 sq cm

SKIN SUBSTITUTES - DFU

- Diabetic neuropathic foot
- Full thickness ulcers that extend through the dermis but do not involve tendon, muscle, joint capsule or bone
- Present greater than 6 weeks
- Failed conservative wound care for at least 4 weeks
- Free from infection
- Adequate blood supply
- Without active Charcot’s arthropathy
- Must document waste
- Know your LCD!
SKIN SUBSTITUTE - VLU

- Indicated for chronic non-healing ulcers
- Venous stasis ulcer
- Full thickness ulcers that extend through the dermis but do not involve tendon, muscle, joint capsule or bone
- Present greater than 3 months/4 weeks
- Failed conservative wound care for at least 8 weeks/2 weeks
- Free from infection and underlying osteomyelitis
- Appropriate steps to off-load pressure during treatment
- Must document waste
- Know your LCD!

DEFINITIONS

Apligraf - Apligraf is supplied as a living, bi-layered skin substitute: the epidermal layer is formed by human keratinocytes and has a well-differentiated stratum corneum; the dermal layer is composed of human fibroblasts in a bovine Type I collagen lattice. While matrix proteins and cytokines found in human skin are present in Apligraf, Apligraf does not contain Langerhans cells, melanocytes, macrophages, lymphocytes, blood vessels or hair follicles.

Dermagraft - Dermagraft® is a cryopreserved human fibroblast-derived dermal substitute; it is composed of fibroblasts, extracellular matrix, and a bioabsorbable scaffold. Dermagraft is manufactured from human fibroblast cells derived from newborn foreskin tissue. During the manufacturing process, the human fibroblasts are seeded onto a bioabsorbable polyglactin mesh scaffold. The fibroblasts proliferate to fill the interstices of this scaffold and secrete human dermal collagen, matrix proteins, growth factors and cytokines, to create a three-dimensional human dermal substitute containing metabolically active, living cells. Dermagraft does not contain macrophages, lymphocytes, blood vessels, or hair follicles.

Oasis - OASIS® Wound Matrix is an intact matrix naturally derived from porcine small intestinal submucosa (SIS), indicated for the management of wounds.
DOCUMENTATION FOR SKIN SUBSTITUTES

Must indicate medical necessity for each visit

Failed conservative treatment documentation must include type of unsuccessful wound care such as:

- Enzymatic and/or surgical debridement
- Wet-to-dry dressings
- Infection control
- Non-weight bearing

Failed conservative treatment documentation must indicate type of unsuccessful ulcer healing such as:

- No change
- Increase in size
- Increase in depth
- No healthy granulation
- No signs or progress towards healing

SKIN SUBSTITUTES

<table>
<thead>
<tr>
<th>CPT</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4101</td>
<td>APLIGRAF PRODUCT (44 SQ CM) PER SQ CM</td>
</tr>
<tr>
<td>Q4102</td>
<td>OASIS PRODUCT (MULTI SIZES) PER SQ CM</td>
</tr>
<tr>
<td>Q4106</td>
<td>DERMAGRAFT (38 SQ CM) PER SQ CM</td>
</tr>
<tr>
<td>15271</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 25 SQ CM, TRUNK/ARMS/LEGGS</td>
</tr>
<tr>
<td>15272</td>
<td>; EA ADD 25 SQ CM, TRUNK/ARMS/LEGGS</td>
</tr>
<tr>
<td>15273</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 100 SQ CM, TRUNK/ARMS/LEGGS</td>
</tr>
<tr>
<td>15274</td>
<td>; EA ADD 100 SQ CM, TRUNK/ARMS/LEGGS</td>
</tr>
<tr>
<td>15275</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 25 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
<tr>
<td>15276</td>
<td>EA ADD 25 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
<tr>
<td>15277</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 100 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
<tr>
<td>15278</td>
<td>; EA ADD 100 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
</tbody>
</table>
### DERMAGRAFT - SUPPLIED IN 37.5 SQ CM

<table>
<thead>
<tr>
<th>CPT</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4106</td>
<td>DERMAGRAFT PRODUCT</td>
</tr>
<tr>
<td>15271</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 25 SQ CM, TRUNK/ARMS/LEGS</td>
</tr>
<tr>
<td>15272</td>
<td>; EA ADD 25 SQ CM, TRUNK/ARMS/LEGS</td>
</tr>
<tr>
<td>15273</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 100 SQ CM, TRUNK/ARMS/LEGS</td>
</tr>
<tr>
<td>15274</td>
<td>; EA ADD 100 SQ CM, TRUNK/ARMS/LEGS</td>
</tr>
<tr>
<td>15275</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 25 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
<tr>
<td>15276</td>
<td>EA ADD 25 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
<tr>
<td>15277</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 100 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
<tr>
<td>15278</td>
<td>; EA ADD 100 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
</tbody>
</table>

### OASIS - SUPPLIED IN 10.5 SQ CM, 21 SQ CM, 70 SQ CM

<table>
<thead>
<tr>
<th>CPT</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4102</td>
<td>OASIS PRODUCT</td>
</tr>
<tr>
<td>15271</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 25 SQ CM TRUNK/ARMS/LEGS</td>
</tr>
<tr>
<td>15272</td>
<td>; EA ADD 25 SQ CM, TRUNK/ARMS/LEGS</td>
</tr>
<tr>
<td>15273</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 100 SQ CM, TRUNK/ARMS/LEGS</td>
</tr>
<tr>
<td>15274</td>
<td>; EA ADD 100 SQ CM, TRUNK/ARMS/LEGS</td>
</tr>
<tr>
<td>15275</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 25 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
<tr>
<td>15276</td>
<td>EA ADD 25 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
<tr>
<td>15277</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 100 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
<tr>
<td>15278</td>
<td>; EA ADD 100 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
</tbody>
</table>
### GRAFTJACKET

<table>
<thead>
<tr>
<th>CPT</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4107</td>
<td>GRAFTJACKET PER SQ CM</td>
</tr>
<tr>
<td>15271</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 25 SQ CM, TRUNK/ARMS/LEGS</td>
</tr>
<tr>
<td>15272</td>
<td>; EA ADD 25 SQ CM, TRUNK/ARMS/LEGS</td>
</tr>
<tr>
<td>15273</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 100 SQ CM, TRUNK/ARMS/LEGS</td>
</tr>
<tr>
<td>15274</td>
<td>; EA ADD 100 SQ CM, TRUNK/ARMS/LEGS</td>
</tr>
<tr>
<td>15275</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 25 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
<tr>
<td>15276</td>
<td>EA ADD 25 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
<tr>
<td>15277</td>
<td>APPLICATION OF SKIN SUBSTITUTE 1ST 100 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
<tr>
<td>15278</td>
<td>; EA ADD 100 SQ CM, HANDS/FEET/DIGITS</td>
</tr>
</tbody>
</table>

### 2012 CPT CHANGES

<table>
<thead>
<tr>
<th>CPT</th>
<th>Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>15271</td>
<td>Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area up to 00 sq cm; each additional 25 sq cm wound surface area, or part thereof (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>15272</td>
<td>Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>15273</td>
<td>Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area</td>
</tr>
<tr>
<td>15275</td>
<td>Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area</td>
</tr>
<tr>
<td>15276</td>
<td>Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area</td>
</tr>
<tr>
<td>15277</td>
<td>Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area</td>
</tr>
<tr>
<td>15278</td>
<td>Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area</td>
</tr>
</tbody>
</table>
SITE PREPARATION: CPT 15002-15005:
VERBIAGE FROM MEDICARE LCD OF “USAGE ON THE SAME DAY”

In most instances, consistent with FDA product labeling and current CPT language included in the introductory information on the family of Skin Substitute codes that limits the use of these products to clean wounds, CPT code 15002-15005 are not appropriate.

Standard, routine minimal wound preparation is considered a part of the procedure.

*In any instance of utilization of a separate debridement code, there is a high likelihood of Contractor record review; therefore the medical record documentation must clearly support that any amount of separately billed debridement was substantial and was medically reasonable and necessary.*

Providers are reminded that FDA-labeling should be reviewed in order to determine that the skin substitute itself is even indicated in such cases of significant same-day debridement.

WOUND CARE DECODED – Q&A

- **Is Surgical Site Preparation (15002-15005) a component of 15271-15278?**
  
  Yes, Site Preparation is considered a component of 15271-15278 and bundled with the payment from Medicare, *when performed on the same date of service as the DG application.*

- **Is Debridement (11042 and 11045) a component of 15271/15278?**
  
  Yes, Debridement codes are considered a component of 15271-15278 and bundled with the payment from Medicare, *when performed on the same date of service as the DG application.*

- **Will Debridement or Site Preparation completed PRIOR to the first Dermagraft application be reimbursed separately?**
  
  Billing prior to beginning Dermagraft would be a clinical decision by the physician and would be covered at a Medicare Contractor discretion and based on “medical necessity”.
  
  Need to verify local Medicare LCD guidelines relating to coverage of 15002-15005.
  
  Site preparation is valued as part of the G-code; therefore, Medicare would not expect to see this routinely billed for each and every patient “prior” to receiving Dermagraft.
**ICD-9-CM THAT SUPPORT MEDICAL NECESSITY**

**ICD-9 CODES COVERED FOR APLIGRAF**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>250.80*–250.83*</td>
<td>Diabetes with other specified manifestations</td>
</tr>
<tr>
<td>454.0</td>
<td>Varicose veins of lower extremities with ulcer</td>
</tr>
<tr>
<td>454.2</td>
<td>Varicose veins of lower extremities with ulcer and inflammation</td>
</tr>
<tr>
<td>941-949</td>
<td>Blister due to burns/burns</td>
</tr>
<tr>
<td>707.12*–707.15*</td>
<td>Ulcer of lower limb, except decubitus</td>
</tr>
</tbody>
</table>

*Note: Dual diagnosis requirement for coding neuropathic diabetic and venous ulcers. Code the DM or venous disease as the primary diagnosis. Code the ulcer to the specific site for the secondary diagnosis.*

**ICD-9-CM THAT SUPPORT MEDICAL NECESSITY**

**ICD-9 CODES COVERED FOR OASIS**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>250.80*–250.83*</td>
<td>Diabetes with other specified manifestations</td>
</tr>
<tr>
<td>454.0</td>
<td>Varicose veins of lower extremities with ulcer</td>
</tr>
<tr>
<td>454.2</td>
<td>Varicose veins of lower extremities with ulcer and inflammation</td>
</tr>
<tr>
<td>459.31</td>
<td>Chronic venous hypertension w/ulcer</td>
</tr>
<tr>
<td>459.33</td>
<td>Chronic venous hypertension w/ulcer &amp; inflammation</td>
</tr>
<tr>
<td>941-946</td>
<td>Blister due to burns/burns</td>
</tr>
<tr>
<td>707.00*–707.09*</td>
<td>Pressure ulcer (with staging code)</td>
</tr>
<tr>
<td>707.12-707.15</td>
<td>Ulcer of the lower limb, except decubitus</td>
</tr>
</tbody>
</table>

*Note: Dual diagnosis requirement for coding neuropathic diabetic and venous ulcers. Code the DM or venous disease as the primary diagnosis. Code the ulcer to the specific site for the secondary diagnosis.*
ICD-9-CM THAT SUPPORT MEDICAL NECESSITY

ICD-9 CODES COVERED FOR DERMAGRAFT

• 250.80*–250.83* Diabetes with other specified manifestations

• 707.14*–707.15* Ulcer of lower limb, except decubitus

• *Note: Dual diagnosis requirement for coding neuropathic diabetic and venous ulcers. Code the DM neuropathic diabetic and venous ulcers. Code the DM or venous disease as the primary diagnosis. Code the ulcer to the specific site for the secondary diagnosis.

UTILIZATION GUIDELINES

Medicare expects skin substitutes/replacements to be applied according to the manufacturers’ instructions listed below:

Up to **five** applications of *Apligraf®* (Q4101) per wound.

Up to **12 weeks** of *Oasis®* (Q4102) per wound.

Up to **eight** applications of *Dermagraft®* (Q4106) per wound.
MODIFIERS

25 Significant, separately identifiable evaluation and management (E/M) service by the same physician on the same day of the procedure or other service

58 Staged or related procedure or service by the same physician during the postoperative period

59 Distinct procedural service

77 Repeat procedure by another physician

79 Unrelated procedure or service by the same physician during the postoperative period

GY Used to indicate a Medicare service is statutorily not covered and you do not have a signed ABH

JC May be required to indicate skin substitute used as graft

JW May be required to indicate skin substitute wasted

KX May be required to indicate the product was handled, prepared, and applied according to the manufacturers’ instructions

WHY HBO?

Beneficial Effects of Hyperbaric Oxygen Therapy in Wound Healing

Cellular Energy and Metabolism
• Improved local tissue oxygenation
• Improved cellular energy metabolism
• Decreased local tissue edema

Antibacterial Effect
• Directly affects anaerobic organisms
• Improved leukocyte bacterial killing
• Increased effectiveness of antibiotics

Regenerating Wound Tissue Effect
• Reduction of inflammation
• Increase in growth factors and receptors (PDGF, TGF-β, VEGF)
• Promotes activated stem cell release
• Promotes collagen deposition
• Promotes extracellular matrix
• Promotes angiogenesis
HBO PROTOCOL

Treatments are daily, Monday – Friday
Each treatment lasts about 2 hours
Safety precautions are a priority
Physician supervision
  ▪ Must be “on the premises”
  ▪ Must be “readily available”
  ▪ Must have face-to-face contact with patient

HBO APPROVED DIAGNOSES (CMS)

Acute carbon monoxide intoxication (986)
Decompression Illness (993.2, 993.3)
Gas embolism (958.0, 999.1)
Gas gangrene (040.0)
Progressive necrotizing infections (necrotizing fasciitis) (728.86)
Acute peripheral arterial insufficiency (444.21, 444.22, 444.81)
Preparation and preservation of compromised skin grafts (not for primary management of wounds) (996.52)
  ▪ This excludes artificial skin grafts
Chronic refractory osteomyelitis, unresponsive medical and surgical management (730.10, 730.19)
**HBO DIAGNOSES (CONT.’)***

Osteoradionecrosis as an adjunct to conventional treatment (526.89)

Acute traumatic peripheral ischemia.
- Valuable adjunctive treatment to be used in combination with accepted standard therapeutic measures when loss of function, limb, or life is threatened. (902.53, 903.01, 903.1, 904.0, 904.41)

Soft tissue radionecrosis as an adjunct to conventional treatment (990)

Cyanide poisoning (987.7, 989.0)

Actinomycosis, only as an adjunct to conventional therapy when the disease process is refractory to antibiotics and surgical treatment (039.0, 039.4, 039.8, 039.9)

---

**DOCUMENTING HBO THERAPY – H&P IS CRUCIAL!***

**Diabetic Ulcers of the Lower Extremities**
- 250.70-250.73, 707.10-707.15
- Must be re-evaluated every thirty days and show measurable signs of healing

Need: Type I or Type II diabetes with lower extremity diabetic ulcer

Need: Wagner Grade III or higher

Need: Standard wound care for thirty days with no measurable signs of healing. Standard wound care must include all of the following:
- Vascular assessment and correction of problem
- Optimization of nutritional status
- Optimization of glucose control
- Debridement by any means to remove devitalized tissue
- Maintenance of a clean, moist wound bed
- Appropriate offloading

Treatment to resolve infection

Supports: TCOM < 40 mm/Hg

**Wagner Grade IV**

Need

Documentation of wet or dry gangrene of the toes, forefoot, knee, elbow, fingers or any area of the lower extremity with localized gangrene

Wagner Grade III

Need

Documentation of one or more of the following: Osteomyelitis, Osteitis, Tendonitis, Abscess or Pyarthrosis

---

10/10/2012
BILLING FOR HBO

Facility
- Medicare patients billed with HCPCS C1300 for each 30 minutes of HBO
- Commercial patients billed with CPT 99183 and only 1 unit

Physician
- 99183 with unit of 1 for each patient (supervision only)

QUESTIONS?